Michelangelo Mancuso

List of Publications by Year
in descending order

267	20,391	34076	12933
papers	citations	52 h-index	131 g-index

277	277	277	24499
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Brain MRI in Monogenic Cerebral Small Vessel Diseases: A Practical Handbook. Current Molecular Medicine, 2022, 22, 300-311.	0.6	1
2	Adult-onset mitochondrial movement disorders: a national picture from the Italian Network. Journal of Neurology, 2022, 269, 1413-1421.	1.8	10
3	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. Annals of Neurology, 2022, 91, 78-88.	2.8	8
4	Arterial intracranial thrombosis as the first manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report. Neurological Sciences, 2022, 43, 2085-2089.	0.9	11
5	Practical â€œ1-2-3-4-Dayâ€•Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke, 2022, 53, 1540-1549.	1.0	26
6	How to approach a neurogenetics diagnosis in different European countries: The European Academy of Neurology Neurogenetics Panel survey. European Journal of Neurology, 2022, 29, 1885-1891.	1.7	5
7	Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery. Journal of Thrombosis and Thrombolysis, 2022, 54, 309-317.	1.0	2
8	Mitochondrial Ataxias: Molecular Classification and Clinical Heterogeneity. Neurology International, 2022, 14, 337-356.	1.3	7
9	Mitochondrial stroke-like episodes: The search for new therapies. Pharmacological Research, 2022, 180, 106228.	3.1	2
10	A Single mtDNA Deletion in Association with a LMNA Gene New Frameshift Variant: A Case Report. Journal of Neuromuscular Diseases, 2022, 9, 457-462.	1.1	2
11	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke, 2022, 53, 2620-2627.	1.0	28
12	Iron-sensitive MR imaging of the primary motor cortex to differentiate hereditary spastic paraplegia from other motor neuron diseases. European Radiology, 2022, 32, 8058-8064.	2.3	6
13	Complications of mechanical thrombectomy for acute ischemic stroke: Incidence, risk factors, and clinical relevance in the Italian Registry of Endovascular Treatment in acute stroke. International Journal of Stroke, 2021, 16, 818-827.	2.9	32
14	Heritable and non-heritable uncommon causes of stroke. Journal of Neurology, 2021, 268, 2780-2807.	1.8	27
15	Comment on â€œA severe linezolidâ€•induced rhabdomyolysis and lactic acidosis in Leigh syndromeâ€•. Journal of Inherited Metabolic Disease, 2021, 44, 6-7.	1.7	2
16	Clinical features of mtDNA-related syndromes in adulthood. Archives of Biochemistry and Biophysics, 2021, 697, 108689.	1.4	10
17	New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders. , 2021, , 509-532.		0
18	An international classification of inherited metabolic disorders (<scp>ICIMD</scp>). Journal of Inherited Metabolic Disease, 2021, 44, 164-177.	1.7	146

#	Article	IF	Citations
19	Catatonia as prominent feature of stroke-like episode in MELAS. Neurological Sciences, 2021, 42, 383-385.	0.9	2
20	Functional and radiological outcomes after bridging therapy versus direct thrombectomy in stroke patients with unknown onset. European Journal of Neurology, 2021, 28, 209-219.	1.7	9
21	Mitochondrial Syndromes Revisited. Journal of Clinical Medicine, 2021, 10, 1249.	1.0	29
22	Magnitude of blood pressure change and clinical outcomes after thrombectomy in stroke caused by large artery occlusion. European Journal of Neurology, 2021, 28, 1922-1930.	1.7	10
23	Response to Carvalho et al.: Diagnosis of monogenic smallâ€vessel disease â€“ â€œrealâ€•worldâ€•application of the consensus recommendation of the European Academy of Neurology. European Journal of Neurology, 2021, 28, e37.	1.7	0
24	Understanding the Multiple Role of Mitochondria in Parkinsonâ€™s Disease and Related Disorders: Lesson From Genetics and Proteinâ€“Interaction Network. Frontiers in Cell and Developmental Biology, 2021, 9, 636506.	1.8	44
25	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	1.0	7
26	SARS-CoV-2 infection in patients with primary mitochondrial diseases: Features and outcomes in Italy. Mitochondrion, 2021, 58, 243-245.	1.6	3
27	Movement Disorders in Children with a Mitochondrial Disease: A Cross-Sectional Survey from the Nationwide Italian Collaborative Network of Mitochondrial Diseases. Journal of Clinical Medicine, 2021, 10, 2063.	1.0	8
28	Mitochondrial disease in adults: recent advances and future promise. Lancet Neurology, The, 2021, 20, 573-584.	4.9	96
29	Genomeâ€Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis. Annals of Neurology, 2021, 90, 777-788.	2.8	10
30	Therapeutical Management and Drug Safety in Mitochondrial Diseasesâ€”Update 2020. Journal of Clinical Medicine, 2021, 10, 94.	1.0	5
31	Clinical, imaging, biochemical and molecular features in Leigh syndrome: a study from the Italian network of mitochondrial diseases. Orphanet Journal of Rare Diseases, 2021, 16, 413.	1.2	16
32	IER-START nomogram for prediction of three-month unfavorable outcome after thrombectomy for stroke. International Journal of Stroke, 2020, 15, 412-420.	2.9	16
33	An â€œall-wheel driveâ€•proposal to accelerate clinical research in common and rare neurological diseases. Neurological Sciences, 2020, 41, 789-793.	0.9	0
34	Mitochondrial epilepsy: a cross-sectional nationwide Italian survey. Neurogenetics, 2020, 21, 87-96.	0.7	14
35	Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimerâ€™s Disease Reveals Sex Differences. Journal of Alzheimer's Disease, 2020, 78, 1707-1719.	1.2	20
36	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. European Stroke Journal, 2020, 5, 374-383.	2.7	6

#	Article	IF	Citations
37	Oxidative stress biomarkers in Fabry disease: is there a room for them?. Journal of Neurology, 2020, 267, 3741-3752.	1.8	12
38	Primary mitochondrial myopathy. Neurology: Genetics, 2020, 6, e519.	0.9	10
39	Fibroblast growth factor 21 and grow differentiation factor 15 are sensitive biomarkers of mitochondrial diseases due to mitochondrial transfer-RNA mutations and mitochondrial DNA deletions. Neurological Sciences, 2020, 41, 3653-3662.	0.9	9
40	General Anesthesia Versus Conscious Sedation and Local Anesthesia During Thrombectomy for Acute Ischemic Stroke. Stroke, 2020, 51, 2036-2044.	1.0	44
41	Monogenic cerebral smallâ€vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. European Journal of Neurology, 2020, 27, 909-927.	1.7	103
42	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. Neurological Sciences, 2020, 41, 2193-2200.	0.9	3
43	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke, 2020, 51, 2347-2354.	1.0	7
44	Safety of drug use in patients with a primary mitochondrial disease: An international Delphiâ€based consensus. Journal of Inherited Metabolic Disease, 2020, 43, 800-818.	1.7	42
45	Awareness of rare and genetic neurological diseases among italian neurologist. A national survey. Neurological Sciences, 2020, 41, 1567-1570.	0.9	2
46	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. European Stroke Journal, 2019, 4, 55-64.	2.7	4
47	CPEO and Mitochondrial Myopathy in a Patient with DGUOK Compound Heterozygous Pathogenetic Variant and mtDNA Multiple Deletions. Case Reports in Neurological Medicine, 2019, 2019, 1-4.	0.3	1
48	Sarcopenia: A Time for Action. An SCWD Position Paper. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 956-961.	2.9	410
49	Muscle pain in mitochondrial diseases: a picture from the Italian network. Journal of Neurology, 2019, 266, 953-959.	1.8	9
50	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	2.4	32
51	Anticoagulation After Stroke in Patients With Atrial Fibrillation. Stroke, 2019, 50, 2093-2100.	1.0	29
52	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2019, 50, 2168-2174.	1.0	59
53	Myoclonus Epilepsy with Ragged-Red Fibers (MERRF). , 2019, , 101-112.		0
54	Mitochondrial Myopathies, Chronic Progressive External Ophthalmoparesis, and Kearns-Sayre Syndrome. , 2019, , 141-150.		0

#	Article	IF	Citations
55	IER-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Thrombectomy for Stroke. Stroke, 2019, 50, 909-916.	1.0	42
56	Lipomatosis Incidence and Characteristics in an Italian Cohort of Mitochondrial Patients. Frontiers in Neurology, 2019, 10, 160.	1.1	19
57	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
58	Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Research, 2019, 4, 201.	0.9	66
59	Mitochondrial disorders and drugs: what every physician should know. Drugs in Context, 2019, 8, 1-16.	1.0	22
60	Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging. Neuromuscular Disorders, 2018, 28, 414-421.	0.3	14
61	Revealing the Complexity of Mitochondrial DNA-Related Disorders. EBioMedicine, 2018, 30, 3-4.	2.7	7
62	Mitochondrial disorders of the retinal ganglion cells and the optic nerve. Mitochondrion, 2018, 42, 1-10.	1.6	18
63	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. Journal of the American Heart Association, 2018, 7, e010133.	1.6	55
64	Proximal Myopathy due to m.5835G>A Mutation in Mitochondrial MT-TY Gene. Case Reports in Neurological Medicine, 2018, 2018, 1-4.	0.3	4
65	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	1.2	2
66	Oxidative Stress in Cerebral Small Vessel Disease Dizziness Patients, Basally and After Polyphenol Compound Supplementation. Current Molecular Medicine, 2018, 18, 160-165.	0.6	10
67	Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation. CNS and Neurological Disorders - Drug Targets, 2018, 17, 767-779.	0.8	59
68	Novel POLG mutations and variable clinical phenotypes in 13 Italian patients. Neurological Sciences, 2017, 38, 563-570.	0.9	17
69	Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease. European Journal of Heart Failure, 2017, 19, 1701-1709.	2.9	18
70	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. Stroke, 2017, 48, 726-732.	1.0	32
71	Epidemiology and cerebrovascular events related to cervical and intracranial arteries dissection: the experience of the city of Pisa. Neurological Sciences, 2017, 38, 1985-1991.	0.9	10
72	International Workshop:. Neuromuscular Disorders, 2017, 27, 1126-1137.	0.3	58

#	Article	IF	Citations
73	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
74	Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in Medicine, 2017, 19, 1380-1397.	1.1	173
75	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. European Journal of Preventive Cardiology, 2017, 24, 1718-1724.	0.8	6
76	Response to Newman et al.. Genetics in Medicine, 2017, 19, 1380-1380.	1.1	3
77	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Nonâ€“Vitaminâ€K Oral Anticoagulants (RAFâ€NOACs) Study. Journal of the American Heart Association, 2017, 6, .	1.6	89
78	Revisiting mitochondrial ocular myopathies: a study from the Italian Network. Journal of Neurology, 2017, 264, 1777-1784.	1.8	32
79	Aging with Cerebral Small Vessel Disease and Dizziness: The Importance of Undiagnosed Peripheral Vestibular Disorders. Frontiers in Neurology, 2017, 8, 241.	1.1	20
80	Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?. Current Molecular Medicine, 2017, 17, 169-180.	0.6	14
81	Mitochondrial ANT-1 related adPEO leading to cognitive impairment: is there a link?. Acta Myologica, 2017, 36, 25-27.	1.5	6
82	Gly482Ser PGC-1Î± Gene Polymorphism and Exercise-Related Oxidative Stress in Amyotrophic Lateral Sclerosis Patients. Frontiers in Cellular Neuroscience, 2016, 10, 102.	1.8	16
83	Biomarkers and progress of antioxidant therapy for rare mitochondrial disorders. Expert Opinion on Orphan Drugs, 2016, 4, 591-603.	0.5	0
84	Mitochondrial m.3243A>G mutation and carotid artery dissection. Molecular Genetics and Metabolism Reports, 2016, 9, 12-14.	0.4	10
85	Mitochondrial DNA haplogroups may influence Fabry disease phenotype. Neuroscience Letters, 2016, 629, 58-61.	1.0	10
86	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
87	Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics. Journal of the American College of Cardiology, 2016, 68, 1037-1050.	1.2	50
88	Acute encephalopathy of the temporal lobes leading to m.3243A > G. When MELAS is not always MELAS. Mitochondrion, 2016, 30, 148-150.	1.6	3
89	Response to: Mitochondrial neuropathy affects peripheral and cranial nerves and is primary or secondary or both. Neuromuscular Disorders, 2016, 26, 549.	0.3	0
90	â€œMitochondrial neuropathiesâ€: A survey from the large cohort of the Italian Network. Neuromuscular Disorders, 2016, 26, 272-276.	0.3	37

#	Article	IF	Citations
91	Are white matter abnormalities associated with â€œunexplained dizzinessâ€?. Journal of the Neurological Sciences, 2015, 358, 428-431.	0.3	46
92	Are white matter abnormalities a cause of â€œunexplained dizzinessâ€?: A retrospective bi-centre study. Journal of the Neurological Sciences, 2015, 357, e45.	0.3	0
93	Cerebral sinus venous thrombosis. Blood Coagulation and Fibrinolysis, 2015, 26, 505-508.	0.5	9
94	Alzheimerâ€™s Pathogenesis and Its Link to the Mitochondrion. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-8.	1.9	28
95	Genetics of ischaemic stroke in young adults. BBA Clinical, 2015, 3, 96-106.	4.1	27
96	â€œCardioembolic Profileâ€•in Patients with Ischemic Stroke: Data from the Analysis of 1037 Cases. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1287-1290.	0.7	3
97	Robotic gait training improves motor skills and quality of life in hereditary spastic paraplegia. NeuroRehabilitation, 2015, 36, 93-99.	0.5	35
98	Redefining phenotypes associated with mitochondrial DNA single deletion. Journal of Neurology, 2015, 262, 1301-1309.	1.8	68
99	ARE WHITE MATTER ABNORMALITIES A CAUSE OF â€˜UNEXPLAINED DIZZINESSâ€™? A RETROSPECTIVE BIâ€“CENTRE STUDY. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.24-e4.	0.9	1
100	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
101	Hypoparathyroidism in Mitochondrial Disorders. , 2015, , 225-230.		0
102	Lack of Association between Nuclear Factor Erythroid-Derived 2-Like 2 Promoter Gene Polymorphisms and Oxidative Stress Biomarkers in Amyotrophic Lateral Sclerosis Patients. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	1.9	21
103	Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.6	0
104	Delphi consensus on the current clinical and therapeutic knowledge on Andersonâ€“Fabry disease. European Journal of Internal Medicine, 2014, 25, 751-756.	1.0	16
105	Hereditary spastic paraparesis in adults. A clinical and genetic perspective from Tuscany. Clinical Neurology and Neurosurgery, 2014, 120, 14-19.	0.6	22
106	The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender?. Journal of Neurology, 2014, 261, 504-510.	1.8	119
107	Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance. International Journal of Cardiology, 2014, 176, 1396-1398.	0.8	4
108	Cardiac involvement in chronic progressive external ophthalmoplegia. Journal of the Neurological Sciences, 2014, 345, 189-192.	0.3	11

#	Article	IF	Citations
109	Novel MTCYB mutation in a young patient with recurrent strokeâ€like episodes and status epilepticus. American Journal of Medical Genetics, Part A, 2014, 164, 2922-2925.	0.7	6
110	The genetics of ataxia: through the labyrinth of the Minotaur, looking for Ariadneâ€™s thread. Journal of Neurology, 2014, 261, 528-541.	1.8	29
111	Myoclonus in mitochondrial disorders. Movement Disorders, 2014, 29, 722-728.	2.2	33
112	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
113	Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases. Current Molecular Medicine, 2014, 14, 598-602.	0.6	11
114	Amyotrophic Lateral Sclerosis: A Genetic Point of View. Current Molecular Medicine, 2014, 14, 1089-1101.	0.6	3
115	Common Genetic Conditions of Ischemic Stroke to Keep in Mind. Current Molecular Medicine, 2014, 14, 979-984.	0.6	0
116	Mitochondrial DNA (mtDNA) haplotypes and dysfunctions in presbyacusis. Acta Otorhinolaryngologica Italica, 2014, 34, 54-61.	0.7	2
117	Transient ischemic attack in hereditary hemorrhagic telangiectasia. American Journal of Emergency Medicine, 2013, 31, 757.e1-757.e2.	0.7	4
118	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
119	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. Neuroscience Letters, 2013, 556, 1-4.	1.0	34
120	An â€œinflammatoryâ€•mitochondrial myopathy. A case report. Neuromuscular Disorders, 2013, 23, 907-910.	0.3	13
121	Carotid Ultrasound Imaging in a Patient with Acute Ischemic Stroke and Aortic Dissection: A Lesson for the Management of Ischemic Stroke?. International Journal of Stroke, 2013, 8, E53-E54.	2.9	5
122	Psychiatric involvement in adult patients with mitochondrial disease. Neurological Sciences, 2013, 34, 71-74.	0.9	47
123	Phenotypic heterogeneity of the 8344A>G mtDNA â€œMERRFâ€•mutation. Neurology, 2013, 80, 2049-2054.	1.5	157
124	Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer's Disease. Current Neurovascular Research, 2013, 10, 76-80.	0.4	26
125	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Molecular Psychiatry, 2013, 18, 461-470.	4.1	103
126	Levetiracetamâ€•responsive myoclonus in spinocerebellar ataxia type 15. Movement Disorders, 2013, 28, 1465-1465.	2.2	7

#	Article	IF	Citations
127	Joint meeting 49th Congress of the Italian Association of Neuropathology and Clinical Neurobiology (AINPeNC) 39th Congress of the Italian Association for Research on Brain Aging (AIRIC). , 2013, 32, 206-244.		0
128	DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimerâ€™s Disease. Current Alzheimer Research, 2012, 9, 550-554.	0.7	29
129	Fabry Disease With Atypical Neurological Presentation. Neurologist, 2012, 18, 413-414.	0.4	4
130	Tetracyclines and Neuromuscular Disorders. Current Neuropharmacology, 2012, 10, 134-138.	1.4	17
131	Oxidative stress biomarkers in patients with untreated obstructive sleep apnea syndrome. Sleep Medicine, 2012, 13, 632-636.	0.8	67
132	Effects of aerobic training on exercise-related oxidative stress in mitochondrial myopathies. Neuromuscular Disorders, 2012, 22, S172-S177.	0.3	31
133	Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases. Neuromuscular Disorders, 2012, 22, S226-S229.	0.3	38
134	Drugs and mitochondrial diseases: 40 queries and answers. Expert Opinion on Pharmacotherapy, 2012, 13, 527-543.	0.9	28
135	Nerve and muscle involvement in mitochondrial disorders: an electrophysiological study. Neurological Sciences, 2012, 33, 449-452.	0.9	13
136	Quality of Life in Adult Patients with Mitochondrial Myopathy. Neuroepidemiology, 2012, 38, 194-195.	1.1	5
137	Implication of a Genetic Variant at PICALM in Alzheimer's Disease Patients and Centenarians. Journal of Alzheimer's Disease, 2011, 24, 409-413.	1.2	15
138	A novel mitochondrial tRNAIle point mutation associated with chronic progressive external ophthalmoplegia and hyperCKemia. Journal of the Neurological Sciences, 2011, 300, 187-190.	0.3	13
139	No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. Neurobiology of Aging, 2011, 32, 1157-1158.	1.5	18
140	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	1.5	82
141	Cognitive impairment and McArdle disease: Is there a link?. Neuromuscular Disorders, 2011, 21, 356-358.	0.3	9
142	May â€œMitochondrial Eveâ€•and Mitochondrial Haplogroups Play a Role in Neurodegeneration and Alzheimer's Disease?. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	1.1	20
143	Tetracycline treatment in patients with progressive external ophthalmoplegia. Acta Neurologica Scandinavica, 2011, 124, 417-423.	1.0	10
144	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708

#	Article	IF	Citations
145	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	4.1	529
146	Clock T3111C and Per2 C111G SNPs do not influence circadian rhythmicity in healthy Italian population. Neurological Sciences, 2011, 32, 89-93.	0.9	23
147	Inflammatory myopathy in a patient with postural and kinetik tremor. Neurological Sciences, 2011, 32, 1175-1178.	0.9	1
148	POLG1-Related and other â€œMitochondrial Parkinsonismsâ€• an Overview. Journal of Molecular Neuroscience, 2011, 44, 17-24.	1.1	49
149	Metabolic myopathies: functional evaluation by different exercise testing approaches. Musculoskeletal Surgery, 2011, 95, 59-67.	0.7	15
150	Targeting Mitochondrial Dysfunction and Neurodegeneration by Means of Coenzyme Q10 and its Analogues. Current Medicinal Chemistry, 2011, 18, 4053-4064.	1.2	73
151	Oxidative Stress Treatment for Clinical Trials in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2011, 24, 111-126.	1.2	39
152	Anti-Ri-associated paraneoplastic cerebellar degeneration. Report of a case and revision of the literature. Archives Italiennes De Biologie, 2011, 149, 318-22.	0.1	8
153	Current Options in the Treatment of Mitochondrial Diseases. Recent Patents on CNS Drug Discovery, 2010, 5, 203-209.	0.9	19
154	Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders. Current Drug Targets, 2010, 11, 111-121.	1.0	120
155	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	1.2	54
156	Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. Journal of Neurology, 2010, 257, 774-781.	1.8	65
157	Pes cavus and hereditary neuropathies: when a relationship should be suspected. Journal of Orthopaedics and Traumatology, 2010, 11, 195-201.	1.0	11
158	Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatric Disease and Treatment, 2010, 6, 491.	1.0	25
159	Limb-Girdle Muscular Dystrophy-Associated Protein Diseases. Neurologist, 2010, 16, 340-352.	0.4	14
160	A Novel Heteroplasmic tRNASer(UCN) mtDNA Point Mutation Associated With Progressive Ophthalmoplegia and Dysphagia. Diagnostic Molecular Pathology, 2010, 19, 28-32.	2.1	5
161	Association study between XRCC1 gene polymorphisms and sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 122-124.	2.3	14
162	Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2010, 47, 190-194.	1.5	152

#	Article	IF	Citations
163	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. Journal of the Neurological Sciences, 2010, 288, 96-100.	0.3	27
164	Lack of association between the APEX1 Asp148Glu polymorphism and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2010, 31, 353-355.	1.5	12
165	Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscular Disorders, 2010, 20, 44-48.	0.3	84
166	A new truncating MPZ mutation associated with a very mild CMT1 B phenotype. Neuromuscular Disorders, 2010, 20, 817-819.	0.3	3
167	Clinical Features and Pathogenesis of Alzheimerâ€™s Disease: Involvement of Mitochondria and Mitochondrial DNA. Advances in Experimental Medicine and Biology, 2010, 685, 34-44.	0.8	59
168	G41SSOD1mutation: A common ancestor for six ALS Italian families with an aggressive phenotype. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 210-215.	2.3	14
169	D90A-SOD1 mutation in ALS: The first report of heterozygous Italian patients and unusual findings. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 216-219.	2.3	24
170	Mitochondria, Cognitive Impairment, and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2009, 2009, 1-8.	1.1	44
171	Advances in molecular diagnostics for mitochondrial diseases. Expert Opinion on Medical Diagnostics, 2009, 3, 557-569.	1.6	0
172	Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker. Current Molecular Medicine, 2009, 9, 1095-1107.	0.6	38
173	Creutzfeldtâ€“Jakob disease with E200K PRNP mutation: a case report and revision of the literature. Neurological Sciences, 2009, 30, 417-420.	0.9	17
174	Is there a primary role of the mitochondrial genome in Alzheimerâ€™s disease?. Journal of Bioenergetics and Biomembranes, 2009, 41, 411-416.	1.0	22
175	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	9.4	2,155
176	Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutrition Reviews, 2009, 67, 427-438.	2.6	17
177	TARDBP (TDPâ€43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. European Journal of Neurology, 2009, 16, 727-732.	1.7	93
178	Is erythropoietin gene a modifier factor in amyotrophic lateral sclerosis?. Neurobiology of Aging, 2009, 30, 842-844.	1.5	3
179	Coenzyme Q10 and Neurological Diseases. Pharmaceuticals, 2009, 2, 134-149.	1.7	32
180	Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease. CNS and Neurological Disorders - Drug Targets, 2009, 8, 222-231.	0.8	54

#	Article	IF	Citations
181	The first Italian family with evidence of pyramidal impairment as phenotypic manifestation of Silver syndrome BSCL2 gene mutation. Neurological Sciences, 2008, 29, 189-191.	0.9	12
182	Ramsay-Hunt syndrome complicated by unilateral multiple cranial nerve palsies. Neurological Sciences, 2008, 29, 497-498.	0.9	31
183	Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: Case study and effect of deep brain stimulation. Movement Disorders, 2008, 23, 114-118.	2.2	30
184	Mitochondrial DNA single deletion in a patient with postural tremor. Movement Disorders, 2008, 23, 2098-2100.	2.2	4
185	Mitochondria, oxidative stress and PARPâ€1 network: a new target for neuroprotective effects of tetracyclines?. Journal of Physiology, 2008, 586, 2427-2428.	1.3	15
186	Vertebral Artery Dissection Onset Mimics Migraine With Aura in a Graphic Designer. Headache, 2008, 48, 621-624.	1.8	20
187	Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: Report of a family. Journal of Affective Disorders, 2008, 106, 173-177.	2.0	27
188	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Neuroscience Letters, 2008, 444, 83-86.	1.0	11
189	Absence of angiogenic genes modification in Italian ALS patients. Neurobiology of Aging, 2008, 29, 314-316.	1.5	41
190	Novel mitochondrial tRNALeu(CUN) transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype. Neuromuscular Disorders, 2008, 18, 204-209.	0.3	17
191	The mtDNA A8344G â€œMERRFâ€•mutation is not a common cause of sporadic Parkinson disease in Italian population. Parkinsonism and Related Disorders, 2008, 14, 381-382.	1.1	13
192	Progressive External Ophthalmoplegia and Vision and Hearing Loss in a Patient With Mutations in POLG2 and OPA1. Archives of Neurology, 2008, 65, 125-31.	4.9	46
193	DPP6 gene variability confers increased risk of developing sporadic amyotrophic lateral sclerosis in Italian patients. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1085-1085.	0.9	20
194	Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?. Current Alzheimer Research, 2008, 5, 457-468.	0.7	54
195	Mitochondrial non-syndromic sensorineural hearing loss: a clinical, audiological and pathological study from Italy, and revision of the literature. Bioscience Reports, 2008, 28, 49-59.	1.1	27
196	Molecular diagnostics and mitochondrial dysfunction: a future perspective. Expert Review of Molecular Diagnostics, 2008, 8, 531-549.	1.5	6
197	Disulfiram neuropathy: Two cases of distal axonopathy. Clinical Toxicology, 2008, 46, 314-316.	0.8	25
198	Mitochondrial DNA sequence variation and neurodegeneration. Human Genomics, 2008, 3, 71.	1.4	35

#	Article	IF	Citations
199	Multiple Cranial Nerve Palsies in Testicular Lymphoma: Report of a Case. Neurologist, 2007, 13, 222-224.	0.4	2
200	M.P.1.13 Novel mitochondrial tRNA LEU(CUN) transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype. Neuromuscular Disorders, 2007, 17, 771.	0.3	0
201	MERRF syndrome without ragged-red fibers: The need for molecular diagnosis. Biochemical and Biophysical Research Communications, 2007, 354, 1058-1060.	1.0	28
202	A Ser326Cys polymorphism in the DNA repair gene hOGG1 is not associated with sporadic Alzheimer's disease. Neuroscience Letters, 2007, 414, 282-285.	1.0	45
203	Association of the hOGG1 Ser326Cys polymorphism with sporadic amyotrophic lateral sclerosis. Neuroscience Letters, 2007, 420, 163-168.	1.0	36
204	Mitochondrial Cascade Hypothesis of Alzheimer's Disease: Myth or Reality?. Antioxidants and Redox Signaling, 2007, 9, 1631-1646.	2.5	48
205	A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement. Journal of the Neurological Sciences, 2007, 263, 40-43.	0.3	18
206	Mitochondrial diseases: a nosological update. Acta Neurologica Scandinavica, 2007, 115, 211-221.	1.0	44
207	Mitochondrial DNA-related Disorders. Bioscience Reports, 2007, 27, 31-37.	1.1	27
208	Functional Diagnostics in Mitochondrial Diseases. Bioscience Reports, 2007, 27, 53-67.	1.1	43
209	Mitochondria and Neurodegeneration. Bioscience Reports, 2007, 27, 87-104.	1.1	125
210	Mitochondrial Syndromic Sensorineural Hearing Loss. Bioscience Reports, 2007, 27, 113-123.	1.1	22
211	Mitochondrial Diseases: Therapeutic Approaches. Bioscience Reports, 2007, 27, 125-137.	1.1	113
212	Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. Journal of Neurology, 2007, 254, 575-580.	1.8	53
213	Lack of association between mtDNA haplogroups and Alzheimerâ€™s disease in Tuscany. Neurological Sciences, 2007, 28, 142-147.	0.9	41
214	Antimyoclonic effect of levetiracetam in MERRF syndrome. Journal of the Neurological Sciences, 2006, 243, 97-99.	0.3	52
215	Novel spastin (SPG4) mutations in Italian patients with hereditary spastic paraplegia. Neuromuscular Disorders, 2006, 16, 387-390.	0.3	15
216	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 10, 371-378.	1.2	30

#	Article	IF	Citations
217	Auditory neuropathy in a patient with mitochondrial myopathy and multiple mtDNA deletions. Journal of Laryngology and Otology, 2006, 120, 888-891.	0.4	10
218	Mitochondrial dysfunction and Alzheimer's disease: New developments. Journal of Alzheimer's Disease, 2006, 9, 111-117.	1.2	25
219	Mitochondrial dysfunction, oxidative stress and neurodegeneration. Journal of Alzheimer's Disease, 2006, 10, 59-73.	1.2	189
220	Genes and the Environment in Neurodegeneration. Bioscience Reports, 2006, 26, 341-367.	1.1	94
221	Early-onset familial parkinsonism due toPOLGmutations. Annals of Neurology, 2006, 59, 859-862.	2.8	248
222	Coenzyme Q10 and Neurological Diseases: An Update. Letters in Drug Design and Discovery, 2006, 3, 378-382.	0.4	1
223	Abdominal Pseudohernia Caused by Herpes Zoster Truncal D12 Radiculoneuropathy. Archives of Neurology, 2006, 63, 1327.	4.9	18
224	New DGK Gene Mutations in the Hepatocerebral Form of Mitochondrial DNA Depletion Syndrome. Archives of Neurology, 2005, 62, 745.	4.9	42
225	Hereditary Ferritinopathy: A Novel Mutation, Its Cellular Pathology, and Pathogenetic Insights. Journal of Neuropathology and Experimental Neurology, 2005, 64, 280-294.	0.9	136
226	Novel Mitochondrial DNA ND5 Mutation in a Patient With Clinical Features of MELAS and MERRF. Archives of Neurology, 2005, 62, 473.	4.9	67
227	Neurology residency training in Europe: an Italian perspective. Lancet Neurology, The, 2005, 4, 258-262.	4.9	11
228	Progressive external ophthalmoplegia: A new family with tremor and peripheral neuropathy. American Journal of Medical Genetics, Part A, 2005, 135A, 217-219.	0.7	19
229	POLG mutations and Alpers syndrome. Annals of Neurology, 2005, 57, 921-923.	2.8	131
230	Congenital or late-onset myopathy in patients with the T14709C mtDNA mutation. Journal of the Neurological Sciences, 2005, 228, 93-97.	0.3	14
231	A novel mitochondrial tRNA ^{Phe} mutation causes MERRF syndrome. Neurology, 2004, 62, 2119-2121.	1.5	81
232	POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology, 2004, 62, 316-318.	1.5	93
233	Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis, 2004, 19, 43-49.	1.0	28
234	A Novel Polymerase Î³ Mutation in a Family With Ophthalmoplegia, Neuropathy, and Parkinsonism. Archives of Neurology, 2004, 61, 1777.	4.9	97

#	Article	IF	Citations
235	A non-syndromic hearing loss caused by very low levels of the mtDNA A3243G mutation. Acta Neurologica Scandinavica, 2004, 110, 72-74.	1.0	20
236	Mitochondrial Encephalomyopathies: Diagnostic Approach. Annals of the New York Academy of Sciences, 2004, 1011, 217-231.	1.8	49
237	Mitochondrial Encephalomyopathies: Therapeutic Approach. Annals of the New York Academy of Sciences, 2004, 1011, 232-245.	1.8	55
238	Hepato-cerebral syndrome: genetic and pathological studies in an infant with a dGK mutation. Acta Neuropathologica, 2004, 108, 168-71.	3.9	11
239	Could mitochondrial haplogroups play a role in sporadic amyotrophic lateral sclerosis?. Neuroscience Letters, 2004, 371, 158-162.	1.0	67
240	Mitochondrial Encephalomyopathies. , 2004, , 232-245.		0
241	Mitochondrial Encephalomyopathies. , 2004, , 217-231.		0
242	Spinal muscular atrophy and mitochondrial DNA depletion. Acta Neuropathologica, 2003, 105, 621-622.	3.9	9
243	The quality of neurology residency programmes in Italy. Lancet Neurology, The, 2003, 2, 594.	4.9	2
244	Lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies. Annals of Neurology, 2003, 54, 524-526.	2.8	58
245	Quality of neurology residency programmes: an Italian survey. European Journal of Neurology, 2003, 10, 301-306.	1.7	9
246	Mitochondrial myopathy and complex III deficiency in a patient with a new stop-codon mutation (G339X) in the cytochrome b gene. Journal of the Neurological Sciences, 2003, 209, 61-63.	0.3	37
247	Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Experimental Neurology, 2003, 182, 421-426.	2.0	70
248	Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscular Disorders, 2003, 13, 162-165.	0.3	95
249	Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscular Disorders, 2003, 13, 813-821.	0.3	198
250	Muscle Glycogenosis and Mitochondrial Hepatopathy in an Infant With Mutations in Both the Myophosphorylase and Deoxyguanosine Kinase Genes. Archives of Neurology, 2003, 60, 1445.	4.9	27
251	Mitochondrial Myopathy of Childhood Associated With Mitochondrial DNA Depletion and a Homozygous Mutation (T77M) in the TK2 Gene. Archives of Neurology, 2003, 60, 1007.	4.9	57
252	Clinical and Genetic Heterogeneity in Progressive External Ophthalmoplegia Due to Mutations in Polymerase Î³. Archives of Neurology, 2003, 60, 1279-84.	4.9	104

#	Article	IF	Citations
253	Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. American Journal of Neuroradiology, 2003, 24, 1958-66.	1.2	72
254	Mitochondrial DNA depletion. Neurology, 2002, 59, 1197-1202.	1.5	156
255	A screening for superoxide dismutase-1 D90A mutation in Italian patients with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 215-218.	1.4	9
256	Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiology of Aging, 2002, 23, 371-376.	1.5	333
257	Peripheral Benzodiazepine Binding Sites in Platelets of Patients Affected by Mitochondrial Diseases and Large Scale Mitochondrial DNA Rearrangements. Molecular Medicine, 2002, 8, 841-846.	1.9	14
258	Mitochondrial DNA depletion anddGKgene mutations. Annals of Neurology, 2002, 52, 311-317.	2.8	152
259	Human mitochondrial transcription factor A reduction and mitochondrial dysfunction in Hashimoto's hypothyroid myopathy. Molecular Medicine, 2002, 8, 326-33.	1.9	10
260	Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Research Bulletin, 2001, 56, 405-410.	1.4	33
261	Sudden bilateral hearing loss and sporadic mitochondrial DNA deletion. Journal of Laryngology and Otology, 2001, 115, 128-131.	0.4	6
262	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 685-687.	0.9	35
263	Cytogenetic damage in peripheral lymphocytes of mitochondrial disease patients. Neurological Sciences, 2000, 21, S963-S965.	0.9	8
264	Abnormal levels of human mitochondrial transcription factor A in skeletal muscle in mitochondrial encephalomyopathies. Neurological Sciences, 2000, 21, S985-S987.	0.9	16
265	Epidemiology of dystrophinopathies in North-West Tuscany: a molecular genetics-based revisitation. Clinical Genetics, 1999, 56, 51-58.	1.0	24
266	Encephalomyopathy with multiple mitochondrial DNA deletions and multiple symmetric lipomatosis: further evidence of a possible association. Journal of Neurology, 1999, 246, 1197-1198.	1.8	5
267	Emostati nella pratica angiografica ed interventistica. The Neuroradiology Journal, 1995, 8, 721-725.	0.1	0